Frontiers in Immunology · 2019 · 18 citations · 17 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyImmune Response To VaccinationImmunological MemoryVaccinationVaccine EffectivenessVaccine EfficacyVaccine-preventable DiseasesCellular MemoryHumoral Immune MemoryImmune Memory AssessmentImmunological Memory FormationPediatric VaccinationProtective Immunological MemorySeroconversion RatesVaccine-induced Immune Memory
= 98) originally enrolled in the dose-response study in 2009 and 46 non-vaccinated controls. Our results demonstrated that vaccinees, who had seroconverted following primary vaccination and had not been revaccinated, present similar neutralizing antibodies levels and YF-specific cellular memory, particularly CMCD4 and EMCD8 as compared to the reference full dose (27,476IU). Although, PRNT seropositivity rates were similar across subgroups (94, 82, 83, 94, 80, and 91%, correspondingly), only doses above 587IU elicited similar iterative proportion of seropositivity rates, calculated as a progressive decrease on seropositivity rates along time (89, 80, 80, and 91%, respectively) as compared to 158IU and 31IU (68 and 46%, respectively). Noteworthy were the strong positive correlations ("EMCD4,EMCD8" and "TNFCD8,IFNCD8") observed in most subdoses, except for 31IU. Major similarities underscored the preserved antibody titers and the outstanding levels of EMCD8, relevant correlates of protection for YF-specific immunity. These findings provide evidences to support the regular use of dose sparing strategy for YF vaccine in adults.
17
Barbara Reinhardt, Robert Jaspert, Matthias Niedrig et al. · Journal of Medical Virology · 1998 · 207 citations